PRESS RELEASE AB SCIENCE REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026 AND KEY EVENTS OF THE PERIOD Change in AB ...
AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd's Syndicate 1902, for its Phase III clinical trial ...
AB Science S.A. considered that its development plan will need to be adapted as follows: Step 2: Resumption of the phase 1 study in acute myeloid leukemia (compound AB8939) within the framework of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results